Alteration of lipids and the transcription of lipid-related genes in myelodysplastic syndromes via a TP53-related pathway

Experimental Hematology

Volumn 40, Issue 7, 2012, Pages

  Ellis, Martin H ^a,b   Baraf, Lior ^a   Shaish, Aviv ^c   Har Zahav, Adi ^b,c   Harats, Dror ^b,c   Ashur Fabian, Osnat ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROTEIN P21; PROTEIN P53; RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BONE MARROW BIOPSY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER PARENCHYMA; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TEMPERATURE SENSITIVITY; TRANSCRIPTION REGULATION;

MUS;

EID: 84862576157     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.02.003     Document Type: Article

References (43)

1. Kawankar N., Vundinti B.R. Cytogenetic abnormalities in myelodysplastic syndrome: an overview. Hematology 2001, 16:131-138.
2. Allampallam K., Dutt D., Nair C., et al. The clinical and biologic significance of abnormal lipid profiles in patients with myelodysplastic syndromes. J Hematother Stem Cell Res 2000, 9:247-255.
3. Kesaniemi Y.A., Witztum J.L., Steinbrecher U.P. Receptor-mediated catabolism of low density lipoprotein in man. Quantitation using glucosylated low density lipoprotein. J Clin Invest 1983, 71:950-959.
4. Aylon Y., Oren M. Living with p53, dying of p53. Cell 2007, 130:597-600.
5. Weisz L., Oren M., Rotter V. Transcription regulation by mutant p53. Oncogene 2007, 26:2202-2211.
6. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2:594-604.
7. el-Deiry W.S., Tokino T., Velculescu V.E., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
8. Bejar R., Stevenson K., Abdel-Wahab O., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
9. Nagoshi H., Horiike S., Kuroda J., Taniwaki M. Cytogenetic and molecular abnormalities in myelodysplastic syndrome. Curr Mol Med 2011, 11:678-685.
10. Ashur-Fabian O., Har-Zahav A., Shaish A., et al. apoB and apobec1, two genes key to lipid metabolism, are transcriptionally regulated by p53. Cell Cycle 2010, 9:3761-3770.
11. Xiao C., Hsieh J., Adeli K., Lewis G.F. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am J Physiol Endocrinol Metab 2011, 301:E429-E446.
12. Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 2008, 9:125-138.
13. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC Press, Lyon, France, pp. 87-104. 4th edition.
14. Chyou P.H., Nomura A.M., Stemmermann G.N., Kato I. Prospective study of serum cholesterol and site-specific cancers. J Clin Epidemiol 1992, 45:287-292.
15. Patel P.S., Shah M.H., Jha F.P., et al. Alterations in plasma lipid profile patterns in head and neck cancer and oral precancerous conditions. Indian J Cancer 2004, 41:25-31.
16. Shetty V., Allampallam K., Raza A. Increased macrophages, high serum M-CSF and low serum cholesterol in myelodysplasia and Kawasaki disease. Br J Haematol 1999, 106:1068.
17. Chen C.W., Cheng H.H. A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes. J Nutr 2006, 136:1472-1476.
18. Plat J., Mensink R.P. Effects of plant stanol esters on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase mRNA expression in mononuclear blood cells of healthy men and women. FASEB J 2002, 16:258-260.
19. Jurevics H., Hostettler J., Barrett C., Morell P., Toews A.D. Diurnal and dietary-induced changes in cholesterol synthesis correlate with levels of mRNA for HMG-CoA reductase. J Lipid Res 2000, 41:1048-1054.
20. Brown M.S., Kovanen P.T., Goldstein J.L. Regulation of plasma cholesterol by lipoprotein receptors. Science 1981, 212:628-635.
21. Raza A., Gezer S., Mundle S., et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995, 86:268-276.
22. Boudard D., Sordet O., Vasselon C., et al. Expression and activity of caspases 1 and 3 in myelodysplastic syndromes. Leukemia 2000, 14:2045-2051.
23. Elghetany M.T. P53 overexpression in bone marrow biopsies in refractory anemia and aplastic anemia: impact of antibody selection. Leuk Res 2000, 24:975-977.
24. Kitagawa M., Yamaguchi S., Takahashi M., et al. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 1998, 12:486-492.
25. Kitagawa M., Yoshida S., Kuwata T., Tanizawa T., Kamiyama R. p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia. Am J Pathol 1994, 145:338-344.
26. Lepelley P., Soenen V., Preudhomme C., Merlat A., Cosson A., Fenaux P. bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis. Leukemia 1995, 9:726-730.
27. Neubauer A., Brendel C., Vogel D., Schmidt C.A., Heide I., Huhn D. Detection of p53 mutations using nonradioactive SSCP analysis: p53 is not frequently mutated in myelodysplastic syndromes (MDS). Ann Hematol 1993, 67:223-226.
28. Kurotaki H., Tsushima Y., Nagai K., Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol 2000, 102:115-123.
29. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci 2000, 910:121-137.
30. Ugalde A.P., Ramsay A.J., de la Rosa J., et al. Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53. EMBO J 2011, 30:2219-2232.
31. Kemp C.J., Sun S., Gurley K.E. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res 2001, 61:327-332.
32. Hong Y.M., Kim H.S., Yoon H.R. Serum lipid and fatty acid profiles in adriamycin-treated rats after administration of L-carnitine. Pediatr Res 2002, 51:249-255.
33. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010, 7:564-575.
34. Ammar el SM, Said SA, Suddek GM, El-Damarawy SL. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats. Can J Physiol Pharmacol. 2011;89:269-276.
35. He L., Rong X., Jiang J.M., Liu P.Q., Li Y. Amelioration of anti-cancer agent adriamycin-induced nephrotic syndrome in rats by Wulingsan (Gorei-San), a blended traditional Chinese herbal medicine. Food Chem Toxicol 2008, 46:1452-1460.
36. El-Shitany N.A., El-Haggar S., El-Desoky K. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol 2008, 46:2422-2428.
37. Boonsanit D., Kanchanapangka S., Buranakarl C. L-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats. Nephrology (Carlton) 2006, 11:313-320.
38. Deepa P.R., Varalakshmi P. Beneficial cardio-renovascular effects of a low-molecular-weight heparin-derivative on adriamycin-induced glycosaminoglycanuria and tissue lipid abnormalities. Toxicology 2005, 211:77-85.
39. Malarkodi K.P., Balachandar A.V., Varlakshmi P. The influence of lipoic acid on adriamycin-induced hyperlipidemic nephrotoxicity in rats. Mol Cell Biochem 2003, 247:139-145.
40. Badary O.A., Abdel-Naim A.B., Abdel-Wahab M.H., Hamada F.M. The influence of thymoquinone on doxorubicin-induced hyperlipidemic nephropathy in rats. Toxicology 2000, 143:219-226.
41. Kim C., Kim N., Joo H., et al. Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin. J Cardiovasc Pharmacol 2005, 46:200-210.
42. Rudling M. Hepatic mRNA levels for the LDL receptor and HMG-CoA reductase show coordinate regulation in vivo. J Lipid Res 1992, 33:493-501.
43. Powell E.E., Kroon P.A. Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in human liver. J Clin Invest 1994, 93:2168-2174.